Aurinia Pharmaceuticals Inc. (AUPH) Stock Analysis — Probabli.AI
AI-powered analysis for AUPH (Aurinia Pharmaceuticals Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
Last price: $16.65 · Market cap: $2.3B · AI outlook: Bullish
Aurinia Pharmaceuticals (AUPH) is positioned favorably in the specialty biopharmaceutical sector, supported by the continued commercial growth of Lupkynis for lupus nephritis. The company exhibits exceptional operational execution, evidenced by an 8-quarter earnings beat streak, an average EPS surprise exceeding +40%, and upwardly revised guidance for FY2026. Trading near $16.65 with a market…
Probabilistic 1-Year Outlook
- Bull 55% · Neutral 30% · Bear 15%
- 1-year price estimates — P10: $14 / P50: $20 / P90: $25
- Aurinia demonstrates strong commercial execution for Lupkynis, evidenced by an 8-quarter earnings beat streak and recent upward revisions to revenue guidance. Robust 17.4% top-line growth and a +41.3% average EPS…
5-Year Outlook
- Bull 50% · Neutral 30% · Bear 20%
- 5-year price estimates — P10: $14 / P50: $32 / P90: $52
SWOT Highlights
- Strength: First FDA-approved oral therapy specifically indicated for lupus nephritis (Lupkynis)
- Strength: Exceptional execution history with 8 consecutive quarters beating earnings estimates and +41.3% avg EPS surprise
- Risk: High revenue concentration on a single approved asset (Lupkynis / voclosporin)
- Risk: Past pipeline setbacks limiting internal clinical-stage pipeline breadth
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
7 Wall Street analysts rate AUPH a BUY with a mean price target of $18.33.
Last analyzed · Model: gemini-3.8-flash. How this forecast works · Accuracy & validation.
AUPH forecast details · AUPH sentiment details
Recent saved forecast research
AI-generated research records, not evaluated investment results.
- Aurinia Pharmaceuticals Inc. (AUPH) — saved
Aurinia Pharmaceuticals (AUPH) is positioned favorably in the specialty biopharmaceutical sector, supported by the continued commercial growth of Lupkynis for lupus nephritis. The company exhibits exceptional operational execution, evidence
- Aurinia Pharmaceuticals Inc. (AUPH) — saved
Aurinia Pharmaceuticals Inc. demonstrates strong growth potential due to its consistent earnings beats and promising drug pipeline. Despite supply chain issues and competitive pressures, the company's fundamentals and positive news highligh
- Aurinia Pharmaceuticals Inc. (AUPH) — saved
Aurinia Pharmaceuticals Inc. (AUPH) demonstrates robust fundamentals with impressive growth rates, consistent earning surprises, and promising pipeline developments, positioning it for above-market average returns over multiple time horizon
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.